Intratumoral electroporation of plasmid interleukin-12: efficacy and biomarker analyses from a phase 2 study in melanoma (OMS-I100)
2015
Background Recent data from immune checkpoint studies, including studies of anti-PD1 and anti-PDL1 antibodies, suggest that an inflammatory intratumoral milieu is required for an optimal response to immune therapy. Serial biopsy analyses from a phase 1 study demonstrate that transformation of tumor cells with electroporation (EP) of plasmid interleukin-12 (pIL-12) promotes this inflammatory immune milieu. Here we present clinical response data for 30 advanced melanoma patients (pts) treated with pIL-12 EP in a phase 2 trial (OMS-I100). We also present additional safety and more detailed biomarker data demonstrating the promotion of pro-inflammatory genes with pIL-12 EP therapy.
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
6
Citations
NaN
KQI